Skip to main content
. 2022 May 5;7(7):1653–1664. doi: 10.1016/j.ekir.2022.04.097

Table 3.

Summary histopathology by etiologic diagnosis of VR

Category AM-VR Mixed VR TCM-VR
Biopsies (n) 21 36 43
Time (mo) 34.8 ± 77.3 14.4 ± 39.7 8.8 ± 26.5a
Indication, n (%) 14 (66.7) 28 (77.8) 20 (46.5)b
Serum creatinine (μmol/l) 302 ± 225 324 ± 274 252 ± 219
Mean MFI (nil DSA = 0) 4776 ± 7494 3680 ± 5157 348 ± 827b,c
Banff v score 1.5 ± 0.8 1.2 ± 0.5 1.2 ± 0.4
Banff ti score 0.7 ± 0.7 2.2 ± 0.9c 0.8 ± 0.9d
Banff i score 0.2 ± 0.4 2.1 ± 0.7c 0.6 ± 0.9d
Banff t score 0.5 ± 0.6 1.8 ± 0.7c 0.9 ± 0.8d
Banff ptc score 0.6 ± 0.9 1.2 ± 1.0a 0.2 ± 0.5d
Banff g score 0.4 ± 0.9 0.7 ± 0.9 0.3 ± 0.6e
C4dptc score 0.7 ± 1.0 0.6 ± 0.8 0 ± 0b,c
C4dglom score 0.7 ± 0.9 0.5 ± 0.9 0.2 ± 0.4a,b
C4dart score 1.1 ± 0.7 1.4 ± 0.9 0.0 ± 0.3c,d
Recurrent rejection, n (%)f 7 (33.3) 12 (33.3) 15 (34.9)
Graft failure, n (%)f 5 (23.8) 10 (27.8) 3 (7.0)e

AM-VR, antibody-mediated vascular rejection; C4dart, C4d staining of arterial endothelium and intima; C4dglom, endothelial C4d staining of glomerular capillaries; C4dptc, C4d staining of peritubular capillaries; MFI, median fluorescence intensity; TCM-VR, T-cell–mediated vascular rejection; VR, vascular rejection.

Detailed histopathology of VR classified by pathophysiology. Mean ± SD, n (%).

Key:

a

P < 0.05; versus AM-VR (pure).

b

P < 0.01; versus mixed VR.

c

P < 0.001 versus AM-VR (pure).

d

P < 0.001 versus mixed VR.

e

P < 0.05; versus mixed VR.

f

Graft failure and recurrent rejection denominator is per biopsy (including repeat biopsies).